検索結果 - Seock‐Ah Im
-
1
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation 著者: Ahrum Min, Seock Ah Im
出版事項 2020Revisão -
2
-
3
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer 著者: José Baselga, Javier Cortés, Seock‐Ah Im, Emma Clark, Graham Ross, Astrid Kiermaier, Sandra M. Swain
出版事項 2014Artigo -
4
-
5
-
6
-
7
-
8
Antibiotic use during the last days of life in cancer patients 著者: Dong Yoon Oh, J. Kim, Dong‐Wan Kim, Seock‐Ah Im, T.Y. KIM, D. S. Heo, Y-J. Bang, N.K. KIM
出版事項 2006Artigo -
9
Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the... 著者: Sandra M. Swain, Young‐Hyuck Im, Seock‐Ah Im, Valorie F. Chan, David Miles, Adam Knott, Emma Clark, Graham Ross, José Baselga
出版事項 2014Artigo -
10
-
11
-
12
-
13
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer:... 著者: Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn
出版事項 2020Artigo -
14
Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> tri... 著者: Elżbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conté, Seock‐Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark E. Robson, Nadine Tung
出版事項 2023Artigo -
15
-
16
Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract... 著者: Kyoung-Min Cho, Hyunkyung Park, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
出版事項 2016Artigo -
17
-
18
Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer 著者: Dong-Hyeon Ha, Ahrum Min, Seongyeong Kim, Hyemin Jang, So Hyeon Kim, Hee Jun Kim, Han Suk Ryu, Ja‐Lok Ku, Kyung-Hun Lee, Seock‐Ah Im
出版事項 2020Artigo -
19
-
20
<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis 著者: Ming Yin, Jingrong Yan, Eva Martinez‐Balibrea, Francesco Graziano, Heinz‐Josef Lenz, Hyo-Jin Kim, Jacques Robert, Seock‐Ah Im, Wei-Shu Wang, Marie-Christine Etienne-Grimaldi, Qingyi Wei
出版事項 2011Revisão
関連主題
Cancer
Medicine
Internal medicine
Oncology
Breast cancer
Chemotherapy
Metastatic breast cancer
Biology
Confidence interval
Hazard ratio
Pathology
Trastuzumab
Cancer research
Biochemistry
Gastroenterology
Clinical trial
Clinical endpoint
Gene
Genetics
Gynecology
Tamoxifen
Alternative medicine
Adverse effect
Placebo
Estrogen receptor
Immunotherapy
Palbociclib
Fulvestrant
Triple-negative breast cancer
Environmental health